Condition: Platinum-Resistant Fallopian Tube Carcinoma · Platinum-Resistant Primary Peritoneal Carcinoma · PARP Inhibitor · Sponsor: Ronald Buckanovich
This trial will treat patients with platinum resistant ovarian, fallopian tube or primary peritoneal cancer as defined by a progression free interval within six months of completion of most recent platinum-based treatment with a combination of vismodegib and atezolizumab. Despite recent improvements in treatment of ovarian cancer with the introduction of PARP inhibitors, response rates to therapy in the platinum resistant setting remain dismal with response rates of only 10-20% reported for single agent cytotoxic therapies. Given the poor prognosis and limited treatment options for these patients, this population is considered appropriate for trials of novel therapeutic candidates.
This description comes directly from the study's public registry record.
Kelsey Mitch, BSN · 412-641-2357 · adamikka2@upmc.edu
Lucia Borasso, BSN · 412-641-3304 · borrlm@upmc.edu
Always discuss trial participation with your own doctor first.
| UPMC Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05538091